Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.

Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K; Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees.

Circulation. 2004 Oct 26;110(17):2618-26. Epub 2004 Oct 18.

2.

Angiotensin inhibition in heart failure.

McMurray JJ.

J Renin Angiotensin Aldosterone Syst. 2004 Sep;5 Suppl 1:S17-22. Review.

PMID:
15526237
3.

ACE inhibitors in heart failure: what more do we need to know?

Demers C, Mody A, Teo KK, McKelvie RS.

Am J Cardiovasc Drugs. 2005;5(6):351-9. Review.

PMID:
16259523
4.

[CHARM study--new strategy for the treatment of heart failure].

Hasegawa H, Komuro I.

Nihon Rinsho. 2004 May;62(5):995-1002. Review. Japanese.

PMID:
15148833
5.
6.

Exploring new treatment strategies in heart failure.

Swedberg K.

Blood Press Suppl. 2000;1:44-8. Review.

PMID:
11059637
7.

Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.

Plosker GL, Keam SJ.

Pharmacoeconomics. 2006;24(12):1249-72. Review.

PMID:
17129078
8.

Candesartan cilexetil in the treatment of chronic heart failure.

Baguet JP, Barone-Rochette G, Neuder Y.

Vasc Health Risk Manag. 2009;5(1):257-64. Epub 2009 Apr 8. Review.

9.

[Benefits of candesartan in the treatment of symptomatic heart failure--CHARM programme].

Umemoto S, Matsuzaki M.

Nihon Rinsho. 2004 Jan;62(1):211-8. Review. Japanese.

PMID:
14737855
10.

Candesartan cilexetil: a review of its use in the management of chronic heart failure.

Fenton C, Scott LJ.

Drugs. 2005;65(4):537-58. Review.

PMID:
15733014
12.

Current perspectives for AT(1)-receptor blockers in the management of heart failure.

Swedberg K.

J Hum Hypertens. 2002 Aug;16 Suppl 3:S47-51. Review.

13.

Improving outcomes in chronic heart failure.

Komajda M.

Drugs Today (Barc). 2006 Dec;42 Suppl C:29-36. Review.

PMID:
17245479
15.

Angiotensin receptor blockers for heart failure.

Heran BS, Musini VM, Bassett K, Taylor RS, Wright JM.

Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003040. doi: 10.1002/14651858.CD003040.pub2. Review.

PMID:
22513909
16.

The CHARM program: the effects of candesartan for the management of patients with chronic heart failure.

McKelvie RS.

Expert Rev Cardiovasc Ther. 2009 Jan;7(1):9-16. doi: 10.1586/14779072.7.1.9. Review.

PMID:
19105762
17.
18.

Valsartan for the treatment of heart failure.

Latini R, Masson S, Staszewsky L, Maggioni AP.

Expert Opin Pharmacother. 2004 Jan;5(1):181-93. Review.

PMID:
14680446
19.

Left ventricular diastolic dysfunction in diabetic patients: pathophysiology and therapeutic implications.

Tsujino T, Kawasaki D, Masuyama T.

Am J Cardiovasc Drugs. 2006;6(4):219-30. Review.

PMID:
16913823
20.

Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.

Meune C, Wahbi K, Duboc D, Weber S.

J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):368-75. doi: 10.1177/1074248410391667. Epub 2010 Dec 30. Review.

PMID:
21193681

Supplemental Content

Support Center